Fennec Pharmaceuticals Inc. Common Stock 2026 Q2 Earnings Call

Thank you, operator, and good morning, everyone. We would like to thank you for joining us. We are pleased to host Fennec Pharmaceuticals' second quarter 2026 earnings conference call today, during which we will review our financial results as well as provide a general business update. Joining me from Fennec this morning is our Chief Executive Officer and board member, Jeff Hackman, our Chief Commercial Officer, Terry Evans, and our Chief Medical Officer, Dr. Pierre Sayad. I am also pleased to welcome our Chief Strategy Officer, Christi Cioffi, who is joining our earnings call for the first time. Christi has more than two decades of leadership experience spanning commercial strategy, brand building, and organizational development, including nearly 15 years of expertise leading award-winning commercialization and launch strategies across the product life cycle.

She has held senior commercial leadership roles at a number of leading biopharmaceutical companies, including Shield Therapeutics, Stemline Therapeutics, EUSA Pharma, Karyopharm Therapeutics, Servier, and Abbott Laboratories, where she helped build and grow oncology, rare disease, and hematology brands from early development through commercialization. As a graduate of West Point, Christi also served our country as a decorated U.S. Army veteran and Bronze Star recipient, leading soldiers during two deployments in Operation Iraqi Freedom. Later in the call, Christi will speak to how recent cross-functional efforts are supporting our long-term growth plans. Additionally, Dr. Pierre Sayad will provide a medical affairs update, and Terry Evans will speak to our commercial progress.

Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the United States Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com, where it will be available for the next 30 days. I will now turn the call over to Jeff Hackman.

Thank you, Robert, and good morning, everyone. Thank you all for joining us here today. Before we dive into the quarter, I would like to take a moment to reflect on how far we have come as an organization. Two years ago, I joined Fennec with clear objectives: build the team, sharpen our execution, and position the company for sustainable long-term growth. Over that time, we have built a talented and experienced leadership team, deep expertise across commercial, medical affairs, clinical development, and corporate strategy. Today, you will have the opportunity to hear from each of them about the progress that they are making in their business. We also expanded our customer-facing team, as you know, to reach a larger prescriber target base with a greater frequency, increasing the numbers from 1,300 to roughly 5,000 targets.

Together, we have built an organization that is focused, accountable, and aligned around delivering for our patients, our healthcare providers, and our shareholders. I am proud of what we accomplished. Since I joined the company, we have increased revenue by 143%, driven by a unified strategy, consistent execution, and a disciplined focus on the fundamentals of our business. Perhaps most importantly, we have demonstrated that this is not the result of any single initiative or quarter. It has been built through steady execution, expanding our commercial reach, strengthening our clinical evidence base, investing in targeted talent across this organization, and maintaining a strong financial foundation. Today's results, including our seventh consecutive quarter of growth, reflect momentum we have created and the commitment of our entire organization.

I would like to thank everyone here and take this opportunity to thank all Fennec employees for their exceptional work to help ensure that these patients facing cancer treatment can continue to hear the moments that make life most meaningful. While we are proud of our progress, we also believe we are still in the early stages of our opportunity. As you will hear today, we are continuing to invest in the drivers that we believe will support long-term growth. From generating additional clinical evidence and expanding physician engagement to building awareness and ensuring that we have resources to execute on our strategies. One of those drivers in Q2 was breaking new ground in a disease awareness campaign, bringing the conversation around testicular cancer to the Indianapolis 500 and introducing Fennec and our mission to millions of fans and forging meaningful connections across the oncology community.

Christi will go much deeper into detail on the impact of this campaign shortly. As a reminder, PEDMARK is currently approved for pediatric patients one month of age and older with localized non-metastatic solid tumors, and is also recognized by the National Comprehensive Cancer Network with a 2A recommendations for use in AYA patients. As we look ahead, we believe the investments we have made across our commercial organization, the clinical evidence generation efforts, and the financial foundation is translating into meaningful momentum. Encouraged by what we have seen so far in the third quarter, we are confident in our ability to continue to build on this progress and deliver sustainable growth. With that, I will turn it over to Christi for a more detailed update on our disease awareness efforts and our presence at ASCO.

Thank you, Jeff. As Jeff just mentioned, over the past two years, we've been very intentional about evolving not only how we position PEDMARK, but also how we engage the oncology community. In 2025, we reinvented our commercial approach with a bold, differentiated branded campaign called Survival Should Be Loud. This campaign challenges convention, resonates strongly with oncologists, and has helped to establish a leadership position for both PEDMARK and Fennec. Building on that momentum, 2026 represents the natural next phase of that evolution. In May, we launched a disruptive disease awareness initiative to wake up a broader audience to the issue of cisplatin-induced hearing loss, or CIO. As we've shared in the past, cisplatin is the cornerstone of testicular cancer treatment, transforming the disease from a frequently fatal diagnosis to one with a cure rate exceeding 95%.

In support of this community, we created an innovative campaign targeting testicular cancer awareness called Indy's Nuts. This campaign, with multiple strategic collaborations, launched at the Indianapolis 500, one of the world's largest sporting events. Through sponsorships with race car driver Jack Harvey and NFL linebacker Alex Singleton, the campaign was intentionally designed to stop people in their tracks. This bold, unexpected creative concept included distribution of over 100,000 bags of peanuts. We sought to capture attention, spark curiosity, and encourage audiences to learn more. Our two important objectives. First, to encourage men to perform regular testicular self-exams and promote earlier diagnosis of testicular cancer. And second, to educate patients diagnosed with testicular cancer about the importance of discussing CIO and hearing prevention with their care teams before treatment begins.

Additionally, we sponsored an educational event with leading KOLs from a renowned institution in the region to deepen understanding of CIO prevention and the role of PEDMARK. Importantly, the initiative demonstrates our ability to reach and engage audiences well beyond traditional healthcare settings, further expanding awareness of both the disease and the unmet needs surrounding CIO. We are extremely pleased by our campaign performance metrics that exceeded industry norms in several categories. The momentum did not stop at the speedway. We carried that same energy and awareness into the ASCO annual meeting, where the racing theme became a natural conversation starter at our booth. Through the draw of racing simulators and interactive experiences, we engaged with oncologists, advanced practitioners, nurses, patient advocates, and industry leaders in meaningful discussions about hearing preservation and the role of PEDMARK in addressing the unmet need of CIO.

Throughout the meeting, the Fennec Speedway generated exceptional engagement and quickly became one of the most talked-about exhibits on the show floor. It was even featured as a part of FiercePharma ASCO's wrap-up article. Our cross-functional team generated hundreds of HCP leads and received overwhelmingly positive feedback from attendees, who appreciated both the interactive education and the important clinical conversation the booth enabled. Pierre will speak more about ASCO shortly. For us, that was the ultimate validation. ASCO wasn't simply memorable. It created an effective platform to educate healthcare professionals, amplify our mission, and reinforce Fennec's leadership in changing the standard of care for the prevention of CIO. With that, I will now turn the call over to Pierre for a medical update.

Thank you, Christi, and good morning, everyone. The second quarter for medical affairs was one defined by expansion.

We have a fully trained, fully deployed MSL team. This team engaged with a record number of new HCPs, as well as affiliated sites and HCOs in Q2, adding significantly to an already growing target base. In fact, our total unique HCP reach increased 63%, and unique affiliated sites increased 72%. This team is successfully converting these scientific field engagements from HCP educational gaps to further clinical conviction as we collaborate across functions to change the standard of care with PEDMARK. During the quarter, we also advanced our evidence generation efforts with impactful presentations at ASCO and through an expanding portfolio of Investigator Sponsored Studies, or ISTs. In April, we announced a third IST with the University of Arizona Cancer Center to evaluate the use of PEDMARK in AYA and adult patients with head and neck and testicular cancers receiving cisplatin.